FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum
NEULANDLAB Share Price Target
Neuland Laboratories Ltd.
Sector: Pharmaceuticals and health care
Sector: Pharmaceuticals and health care
NEULANDLAB Long Term Analysts Rating
- ★★
- ★★
- ★★
- ★★
- ★★
5/5 (2 Ratings)
NEULANDLAB Share Price *
476.5 -7.4 (-1.53%)
* (quote may be delayed)
2 NEULANDLAB share price target reports by brokerages below. See what is analyst's view on NEULANDLAB share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
You can also find NEULANDLAB share price target tomorrow or next week from NEULANDLAB discussion forum.
NEULANDLAB Share Price Forecast - Consensus
| No. of reports in last year | 2 |
| No. of analysts | 1 |
| Average Consensus Forecast | 777.50 |
| Consensus Potential | 37.48% |
NEULANDLAB Share Price Target - Broker Reports - 2019
HDFC Securities
19-Aug-19
Price @ Call: 504.1
Target: 725
BUY
We maintain BUY on NLL following a mixed quarter. Our TP is revised to Rs 725 (14x FY21E EPS). The scale up in lucrative products like Salmeterol and Austedo remain key triggers for improvement in operational performance.
HDFC Securities
15-Feb-19
Price @ Call: 583.15
Target: 830
BUY
NEULANDLAB Share Price Target - Broker Reports - 2018
HDFC Securities
12-May-18
Price @ Call: 793.56
Target: 1000
BUY
HDFC Securities
15-Mar-18
Price @ Call: 697.1
Target: 1065
BUY
NEULANDLAB Share Price Target - Broker Reports - 2017
AnandRathi
26-Sep-17
Price @ Call: 993
Target: 1318
BUY
NEULANDLAB Share Price Target - Broker Reports - 2016
Hem Securities
25-Aug-16
Price @ Call: 1024.1
Target: 1280
BUY
- keyboard_arrow_down
NEULANDLAB Peer Stocks - Share Price Targets
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.